CAJ | 학술논문

脂肪细胞型脂肪酸结合蛋白(A-FABP)是近年来新发现的脂肪因子.动物实验表明其可以促进代谢综合征各组分如胰岛素抵抗、血脂紊乱、2型糖尿病和动脉粥样硬化的发生、发展.人群研究也发现,其过度表达而导致血浆中含量增加是反映代谢综合征的一个可靠生物标志物.随着研究的深入,A-FABP对于治疗代谢综合征的作用也日益受到人们的关注.以下主要就近年来有关A-FABP的分布、结构、特性及其与代谢综合征组分的关系作一综述.
지방세포형지방산결합단백(A-FABP)시근년래신발현적지방인자.동물실험표명기가이촉진대사종합정각조분여이도소저항、혈지문란、2형당뇨병화동맥죽양경화적발생、발전.인군연구야발현,기과도표체이도치혈장중함량증가시반영대사종합정적일개가고생물표지물.수착연구적심입,A-FABP대우치료대사종합정적작용야일익수도인문적관주.이하주요취근년래유관A-FABP적분포、결구、특성급기여대사종합정조분적관계작일종술.
Adipocyte fatty acid-binding protein(A-FABP) is a new-found adipocytokine which secreted from adipocyte. Animal experiment indicated that A-FABP can promote the development of insulin resistance, dyslipidemia, type 2 diabetes mellitns and artheroaclerosis in metabolic syndrome. Population studies found that serum A-FABP level might be an independent biomarker of metabolic syndrome. The effect of A-FABP in treating metabolic syndrome is concerned by people gradually. This article introduces the distribution, structure, property of A-FABP, and the relationship between A-FABP and the components of metabolic syndrome.